In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. René Pareja to discuss Topical Treatments for HPV: Fact or Flawed Science.

Dr. René Pareja is a Gynecologist and Obstetrician, graduated from Universidad Pontificia Bolivariana in Medellín, Colombia in 2000; he finished his training in Gynecologic Oncology in 2003, from Pontificia Universidad Javeriana and Instituto Nacional de Cancerología in Bogotá, Colombia.

He is a minimally invasive surgeon, graduated from Corporación de Estudios de la Salud (CES) in 2013. He currently works at Astorga Oncology Clinic in Medellín and at National Cancer Institute in Bogotá, Colombia.

Dr. Pareja serves as a reviewer for more than 20 journals. He has authored or co-authored ten book chapters and more than 160 publications in peer-reviewed journals. Currently he is an Associate Editor of the International Journal of Gynaecological Cancer. He also serves as an international mentor for the Hospital General San Juan de Dios in Guatemala through the IGCS Global Curriculum & Mentorship Program. Some of his research has influenced how gynecologic oncologists treat cancer and has been published in important medical journals, like the New England Journal of Medicine, and Journal of Clinical Oncology.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Anne-Sophie van den Heerik and Carien Creutzberg to discuss Molecular Profile-Based Adjuvant Treatment Endometrial Cancer: PORTEC-4a.

Anne-Sophie van den Heerik, MD, is a resident in radiation oncologist at the Leiden University Medical Center, The Netherlands. Her work focuses on the integration of molecular classification into endometrial cancer adjuvant therapy decision-making. Her recent publications includes the PORTEC-4a trial and the Cost-utility-analysis of molecular-integrated-profile for women with (high) intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial.

Carien Creutzberg, MD, PhD is Professor of Radiation Oncology at Leiden University Medical Center, The Netherlands. Her work focuses on improving outcomes and quality of life for women with gynaecological cancers, particularly endometrial cancer. She is the principal investigator of the landmark PORTEC trials, which have shaped international treatment guidelines, and is a leading figure in integrating molecular profiling into personalized cancer care.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Robert Wenham and Angeles Alvarez Secord to discuss Pembrolizumab and weekly paclitaxel for platinum-resistant ovarian cancer.

Dr. Robert Wenham is a gynecologic oncologist and Chair of the Gynecologic Oncology Program at Moffitt Cancer Center. Dr. Wenham has a strong interest in research and is a principal investigator for numerous clinical trials to improve cancer care for women. His research activities include the use of novel drugs for the treatment of gynecologic cancers. He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation. Dr. Wenham enjoys the challenge of helping women with complex issues and the opportunity to offer them cutting-edge therapies, from the latest chemotherapy approaches to biologically targeted therapies, minimally invasive surgery, and clinical trials. He is also an expert in pelvic exenteration surgery, a very complex operation that offers hope of a possible cure for certain patients with gynecologic cancer. Clinically, he prefers a more collaborative approach where the patient plays an active role in decisions as he guides them through the pros and cons of their options.

Angeles Alvarez Secord, MD, MHSc, is a professor in the Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University Heath System. She received her undergraduate degree with honors from Carroll College in Helena, Montana and graduated AOA with honors from the University of Washington School of Medicine in Seattle, Washington. Dr. Secord completed her residency in obstetrics and gynecology and her fellowship in gynecologic oncology at the Duke University Medical Center in Durham, North Carolina. Upon completing her fellowship in 2001, she joined the Division of Gynecologic Oncology at Duke. She is currently Director of Gynecologic Oncology Clinical Trials, Associate Director of Clinical Research, Gynecology Oncology, and one of the Principal Investigators for NRG Oncology at the Duke Cancer Institute. Dr. Secord serves on the GOG Foundation Board of Directors. She is passionate about mentoring the next generation of investigators and serves as the GOG Foundation Education and Mentoring Chair and the NRG Oncology Investigator and Career Development Committee Vice-Chair. Dr. Secord is a fellow of the American College of Obstetricians and Gynecologists and an active member of American Society of Clinical Oncology, American Gynecological & Obstetrical Society, Society of Gynecology & Oncology, and International Gynecologic Cancer Society as well as other professional organizations.